JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Home・Aandelen Lijst・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Gesloten

SectorGezondheidszorg

201.69 0.56

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

200.56

Max

202.41

Belangrijke statistieken
By Trading Economics
Inkomsten	56M -39M
Verkoop	57M 158M
Winstmarge	-24.585
Werknemers	1,017
EBITDA	51M 2.3M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+26.88% upside

Dividenden
By Dow Jones
Volgende Winsten	13 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.6B 13B
Vorige openingsprijs	201.13
Vorige sluitingsprijs	201.69

Nieuwssentiment

By Acuity

50%

147 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

157.66 / 167.29 Steun & Weerstand

Ascendis Pharma A-S ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 okt 2025, 18:41 UTC

Winsten

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 okt 2025, 18:31 UTC

Winsten

Correction to Procter & Gamble to Focus on Innovation

24 okt 2025, 16:25 UTC

Belangrijke Marktbewegers

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 okt 2025, 21:24 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 okt 2025, 21:24 UTC

Marktinformatie

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 okt 2025, 21:07 UTC

Winsten

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 okt 2025, 20:58 UTC

Winsten

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 okt 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

24 okt 2025, 20:40 UTC

Winsten

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 okt 2025, 20:24 UTC

Winsten

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 okt 2025, 20:23 UTC

Winsten

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 okt 2025, 20:13 UTC

Winsten

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 okt 2025, 20:07 UTC

Marktinformatie

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 okt 2025, 19:40 UTC

Marktinformatie

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 okt 2025, 19:35 UTC

Marktinformatie

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 okt 2025, 19:33 UTC

Winsten

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 okt 2025, 19:29 UTC

Marktinformatie

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 okt 2025, 18:52 UTC

Winsten

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 okt 2025, 18:41 UTC

Winsten

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 okt 2025, 18:03 UTC

Winsten

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 okt 2025, 18:02 UTC

Winsten

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 okt 2025, 18:00 UTC

Marktinformatie

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 okt 2025, 16:57 UTC

Winsten

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 okt 2025, 16:54 UTC

Marktinformatie

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 okt 2025, 16:44 UTC

Marktinformatie

Winsten

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 okt 2025, 16:39 UTC

Marktinformatie

Winsten

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 okt 2025, 16:33 UTC

Winsten

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 okt 2025, 16:23 UTC

Winsten

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 okt 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

24 okt 2025, 16:07 UTC

Winsten

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Peer Vergelijking

Prijswijziging

Ascendis Pharma A-S ADR Prognose

Koersdoel

By TipRanks

26.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 256.29 USD 26.88%

Hoogste 307 USD

Laagste 220 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ascendis Pharma A-S ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

17 ratings

Buy

Hold

Sell

Gebaseerd op 17 analisten die aandelenratings hebben gegeven aan Ascendis Pharma A-S ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

157.66 / 167.29Steun & Weerstand

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

147 / 371 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.